Sight Sciences, Inc., a medical device company operating within the health care sector, is headquartered in Menlo Park, United States. The company is recognized for its innovative technology-driven solutions aimed at addressing the underlying physiology of ophthalmic diseases. Sight Sciences offers a range of both surgical and non-surgical devices, with a particular focus on technologies for dry eye disease. The company’s global customer base reflects its international reach and influence in the medical device industry.
As of the latest available data, Sight Sciences is listed on the Nasdaq stock exchange, trading under the currency of USD. The company’s stock closed at $5.26 on March 2, 2026. Over the past year, the stock has experienced significant volatility, with a 52-week high of $9.236 recorded on December 25, 2025, and a 52-week low of $2.03 on April 7, 2025. This results in a 52-week range of $7.206, highlighting the fluctuations in investor sentiment and market conditions affecting the company.
The market capitalization of Sight Sciences stands at approximately $297.14 million USD, indicating its size and market presence within the health care sector. However, the company’s financial metrics reveal challenges in terms of profitability. The price-to-earnings (P/E) ratio is currently at -6.07, reflecting a negative earnings environment. This suggests that the company is not generating sufficient earnings to justify a positive P/E ratio. Additionally, the price-to-book (P/B) ratio is 4.24355, indicating that the market values the firm at roughly four times its book value.
The combination of a broad 52-week price range and modest valuation multiples may suggest investor uncertainty regarding the company’s future profitability prospects. Despite these financial challenges, Sight Sciences continues to focus on its core mission of developing advanced medical technologies for ophthalmic diseases.
The most recent public mention of Sight Sciences came from a feed dated February 11, 2026, titled “KCK LTD. Adjusts Holdings in Sight Sciences Inc: A Strategic Portfolio Move.” This indicates that there have been strategic adjustments in the holdings of Sight Sciences by KCK LTD, which could potentially impact the company’s stock performance and investor perception.
For more detailed information about Sight Sciences’ products and services, interested parties are encouraged to visit their official website at www.sightsciences.com .
